Literature DB >> 27613619

Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.

Parisa Farzanehfar1,2.   

Abstract

The motor symptoms of Parkinson's disease (PD) are caused by degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNc) of midbrain. Given the fact that current treatment options are mostly symptomatic and based on increasing DA level in the nigrostriatal system, it is generally believed the most effective and long-lasting treatment for PD motor symptoms will be replacing SNc DA cells, either by endogenous repair (i.e. neurogenesis) or cell transplantation. While cell transplantation is hindered by failure of acquisition and maintenance of the DA phenotype by transplanted cells, hope rests upon non-invasive cell replacement therapy (CRT) with endogenous neural stem cells, which have the potential to give rise to new neurons including DA neurons. Understanding underlying mechanisms and signalling pathways of neurogenesis in the adult brain could shed light on obstacles to achieve effective CRTs and better treatments for PD. This paper first reviews different therapeutic strategies in context of PD along with their advantages and disadvantages followed by an extensive review of adult neurogenesis.

Entities:  

Keywords:  Adult neurogenesis; BrdU+ cells; Midbrain; Parkinson’s disease; Stem cells; Striatum; Substantia Nigra (SN)

Mesh:

Substances:

Year:  2016        PMID: 27613619     DOI: 10.1007/s11064-016-2053-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  111 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain.

Authors:  H G Kuhn; J Winkler; G Kempermann; L J Thal; F H Gage
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

4.  Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

Authors:  C Rosenblad; D Kirik; A Björklund
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

5.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.

Authors:  A Björklund; U Stenevi
Journal:  Brain Res       Date:  1979-11-30       Impact factor: 3.252

6.  Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone.

Authors:  M B Luskin
Journal:  Neuron       Date:  1993-07       Impact factor: 17.173

7.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease.

Authors:  A L Benabid; P Pollak; A Louveau; S Henry; J de Rougemont
Journal:  Appl Neurophysiol       Date:  1987

8.  PSA-NCAM distinguishes reactive astrocytes in 6-OHDA-lesioned substantia nigra from those in the striatal terminal fields.

Authors:  T Nomura; T Yabe; E S Rosenthal; M Krzan; J P Schwartz
Journal:  J Neurosci Res       Date:  2000-09-15       Impact factor: 4.164

9.  Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease.

Authors:  Neelam K Venkataramana; Satish K V Kumar; Sudheer Balaraju; Radhika Chemmangattu Radhakrishnan; Abhilash Bansal; Ashish Dixit; Deepthi K Rao; Madhulita Das; Majahar Jan; Pawan Kumar Gupta; Satish M Totey
Journal:  Transl Res       Date:  2009-08-06       Impact factor: 7.012

10.  GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.

Authors:  Vincent J J Odekerken; Judith A Boel; Ben A Schmand; Rob J de Haan; M Figee; Pepijn van den Munckhof; P Richard Schuurman; Rob M A de Bie
Journal:  Neurology       Date:  2016-01-27       Impact factor: 9.910

View more
  5 in total

Review 1.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

Review 2.  RNA-binding proteins with prion-like domains in health and disease.

Authors:  Alice Ford Harrison; James Shorter
Journal:  Biochem J       Date:  2017-04-07       Impact factor: 3.857

3.  Can Valproic Acid Regulate Neurogenesis from Nestin+ Cells in the Adult Midbrain?

Authors:  Parisa Farzanehfar; Malcolm K Horne; Tim D Aumann
Journal:  Neurochem Res       Date:  2017-04-22       Impact factor: 3.996

4.  Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure.

Authors:  Magda M Melkonyan; Lilit Hunanyan; Ali Lourhmati; Nikolas Layer; Sandra Beer-Hammer; Konstantin Yenkoyan; Matthias Schwab; Lusine Danielyan
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

5.  Safranal-promoted differentiation and survival of dopaminergic neurons in an animal model of Parkinson's disease.

Authors:  Yi Zhao; Gangming Xi
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.